Alyssa Monica Torres Flores, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Peripheral Arterial Disease | 3 | 2022 | 1188 | 0.780 |
Why?
|
Nanotubes, Carbon | 1 | 2020 | 73 | 0.690 |
Why?
|
Phagocytosis | 2 | 2020 | 1539 | 0.600 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2019 | 392 | 0.580 |
Why?
|
Limb Salvage | 1 | 2019 | 433 | 0.570 |
Why?
|
Cardiovascular Agents | 2 | 2020 | 850 | 0.540 |
Why?
|
Myocytes, Smooth Muscle | 4 | 2021 | 687 | 0.540 |
Why?
|
Tears | 1 | 2016 | 256 | 0.490 |
Why?
|
Drug Carriers | 1 | 2019 | 693 | 0.490 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2016 | 437 | 0.440 |
Why?
|
Atherosclerosis | 4 | 2021 | 3445 | 0.410 |
Why?
|
Dry Eye Syndromes | 1 | 2016 | 386 | 0.390 |
Why?
|
Carotid Artery Diseases | 3 | 2021 | 882 | 0.370 |
Why?
|
Vascular Diseases | 1 | 2019 | 1161 | 0.370 |
Why?
|
Ischemia | 1 | 2019 | 1907 | 0.360 |
Why?
|
Macrophages | 3 | 2020 | 5655 | 0.330 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2214 | 0.310 |
Why?
|
Patient Care Team | 1 | 2019 | 2531 | 0.310 |
Why?
|
Nanoparticles | 1 | 2019 | 1905 | 0.300 |
Why?
|
Coronary Artery Disease | 3 | 2021 | 6487 | 0.290 |
Why?
|
Plaque, Atherosclerotic | 4 | 2021 | 1519 | 0.270 |
Why?
|
Endovascular Procedures | 1 | 2019 | 1979 | 0.260 |
Why?
|
Muscle, Smooth, Vascular | 2 | 2021 | 1504 | 0.230 |
Why?
|
Neointima | 2 | 2021 | 135 | 0.210 |
Why?
|
Forecasting | 2 | 2021 | 2951 | 0.190 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2020 | 122 | 0.180 |
Why?
|
Carotid Artery, Common | 1 | 2020 | 183 | 0.180 |
Why?
|
Signal Transduction | 2 | 2020 | 23403 | 0.170 |
Why?
|
Complement Activation | 1 | 2020 | 453 | 0.160 |
Why?
|
Internal Mammary-Coronary Artery Anastomosis | 1 | 2017 | 33 | 0.160 |
Why?
|
Mammary Arteries | 1 | 2017 | 70 | 0.150 |
Why?
|
Gene Expression Regulation | 1 | 2016 | 12072 | 0.150 |
Why?
|
Varicose Veins | 1 | 2018 | 154 | 0.150 |
Why?
|
Nanomedicine | 1 | 2020 | 304 | 0.140 |
Why?
|
Aortic Aneurysm | 1 | 2021 | 643 | 0.140 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2019 | 675 | 0.140 |
Why?
|
Health Plan Implementation | 1 | 2019 | 352 | 0.140 |
Why?
|
Behavior Therapy | 1 | 2021 | 865 | 0.130 |
Why?
|
Lower Extremity | 2 | 2022 | 1158 | 0.130 |
Why?
|
Rats, Inbred F344 | 1 | 2016 | 862 | 0.120 |
Why?
|
Cloning, Molecular | 1 | 2020 | 4320 | 0.120 |
Why?
|
Receptors, Immunologic | 1 | 2020 | 1423 | 0.110 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2019 | 1375 | 0.110 |
Why?
|
Workload | 1 | 2019 | 850 | 0.110 |
Why?
|
Natural Language Processing | 1 | 2021 | 1041 | 0.110 |
Why?
|
Blood Vessels | 1 | 2018 | 1125 | 0.110 |
Why?
|
Lysosomes | 1 | 2018 | 893 | 0.110 |
Why?
|
Body Height | 1 | 2018 | 1577 | 0.100 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2020 | 2016 | 0.100 |
Why?
|
Neovascularization, Pathologic | 2 | 2019 | 2635 | 0.100 |
Why?
|
Molecular Structure | 1 | 2016 | 1899 | 0.100 |
Why?
|
Rupture, Spontaneous | 2 | 2021 | 354 | 0.090 |
Why?
|
Radiopharmaceuticals | 1 | 2020 | 2645 | 0.090 |
Why?
|
Program Evaluation | 1 | 2019 | 2488 | 0.090 |
Why?
|
RNA Interference | 1 | 2019 | 2889 | 0.090 |
Why?
|
Transforming Growth Factor beta | 1 | 2018 | 2007 | 0.090 |
Why?
|
Risk Assessment | 2 | 2021 | 23338 | 0.090 |
Why?
|
Cholesterol | 1 | 2019 | 2917 | 0.090 |
Why?
|
RNA, Small Interfering | 1 | 2019 | 3505 | 0.090 |
Why?
|
Life Style | 1 | 2021 | 3835 | 0.090 |
Why?
|
Genetic Loci | 1 | 2018 | 2575 | 0.080 |
Why?
|
Disease Models, Animal | 4 | 2021 | 18029 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6538 | 0.080 |
Why?
|
Animals | 9 | 2021 | 168757 | 0.080 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2018 | 1186 | 0.080 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2021 | 3327 | 0.080 |
Why?
|
Wound Healing | 1 | 2019 | 2785 | 0.080 |
Why?
|
Bone and Bones | 1 | 2018 | 2575 | 0.080 |
Why?
|
Mice, Transgenic | 1 | 2020 | 9734 | 0.070 |
Why?
|
Cells, Cultured | 3 | 2021 | 19229 | 0.070 |
Why?
|
Mice | 6 | 2021 | 81183 | 0.070 |
Why?
|
Phenotype | 2 | 2021 | 16365 | 0.070 |
Why?
|
Mice, Inbred BALB C | 1 | 2016 | 6386 | 0.070 |
Why?
|
Prospective Studies | 2 | 2021 | 53288 | 0.070 |
Why?
|
Treatment Outcome | 3 | 2022 | 63114 | 0.070 |
Why?
|
Thrombosis | 1 | 2019 | 2968 | 0.060 |
Why?
|
Cell Differentiation | 1 | 2021 | 11483 | 0.060 |
Why?
|
Rats | 2 | 2018 | 24260 | 0.060 |
Why?
|
Humans | 12 | 2022 | 744343 | 0.050 |
Why?
|
Inflammation | 2 | 2020 | 10638 | 0.050 |
Why?
|
Aged | 4 | 2021 | 163280 | 0.050 |
Why?
|
Quality of Life | 1 | 2022 | 12804 | 0.050 |
Why?
|
Algorithms | 1 | 2021 | 13881 | 0.050 |
Why?
|
Prognosis | 1 | 2021 | 29063 | 0.050 |
Why?
|
Antibodies, Blocking | 1 | 2020 | 253 | 0.050 |
Why?
|
Female | 7 | 2020 | 380194 | 0.040 |
Why?
|
Male | 8 | 2020 | 350118 | 0.040 |
Why?
|
Complement C3 | 1 | 2020 | 461 | 0.040 |
Why?
|
Mice, Inbred C57BL | 3 | 2021 | 21827 | 0.040 |
Why?
|
Hydrazones | 1 | 2018 | 102 | 0.040 |
Why?
|
Carotid Arteries | 1 | 2021 | 952 | 0.040 |
Why?
|
Chloroquine | 1 | 2018 | 280 | 0.040 |
Why?
|
Insurance Benefits | 1 | 2017 | 183 | 0.030 |
Why?
|
Endosomes | 1 | 2018 | 520 | 0.030 |
Why?
|
Fibrosis | 1 | 2021 | 2029 | 0.030 |
Why?
|
Phosphates | 1 | 2018 | 786 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2020 | 10481 | 0.030 |
Why?
|
Mendelian Randomization Analysis | 1 | 2018 | 967 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2012 | 0.030 |
Why?
|
Cell Lineage | 1 | 2020 | 2504 | 0.020 |
Why?
|
Mutation | 1 | 2016 | 29786 | 0.020 |
Why?
|
Up-Regulation | 1 | 2020 | 4217 | 0.020 |
Why?
|
Osteogenesis | 1 | 2018 | 1299 | 0.020 |
Why?
|
Middle Aged | 2 | 2021 | 213383 | 0.020 |
Why?
|
Adult | 2 | 2021 | 214055 | 0.020 |
Why?
|
Aorta | 1 | 2018 | 2061 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2018 | 8301 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3255 | 0.020 |
Why?
|
Cohort Studies | 2 | 2018 | 40561 | 0.020 |
Why?
|
Calcium | 1 | 2018 | 5756 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2020 | 15076 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2018 | 12354 | 0.010 |
Why?
|
Risk Factors | 2 | 2022 | 72290 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2018 | 14557 | 0.010 |
Why?
|
United States | 2 | 2022 | 69872 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2018 | 12261 | 0.010 |
Why?
|
Medicare | 1 | 2017 | 6566 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39050 | 0.010 |
Why?
|